The BCLC Update and Future Prospects

发布时间:2010-02 来源:丁香通

Alejandro Forner, M.D.,1,2 Marı´a E. Reig, M.D.,1,2 Carlos Rodriguez de Lope, M.D.,1 and Jordi Bruix, M.D.1,2

ABSTRACT

Staging and treatment indication are relevant topics in the management of patients with hepatocellular carcinoma (HCC) and for optimal results, they have to take into account liver function, tumor stage, and physical status. For any staging system to be meaningful it has to link staging with treatment indication; this should be based on robust scientific data. Currently, the sole proposal that serves both aims is the Barcelona Clinic Liver Cancer (BCLC) approach. It takes into account the relevant parameters of all important dimensions and divides patients into very early/early, intermediate, advanced, and end-stage. Early-stage HCC patients should be considered for potentially curative options such as resection, ablation, and transplantation. Patients at intermediate stage benefit from chemoembolization, whereas patients at an advanced stage, or who cannot benefit from options of higher priority, have sorafenib as the standard treatment. Finally, patients at end-stage should merely receive palliative care. KEYWORDS: Hepatocellular carcinoma, staging, prognosis, treatment, survival

原文链接:http://pubmed.cn/20175034

L.CN.MKT.SM.10.2016.0903

获取全文请填写您的电子邮箱地址,以便我们把文章发送到您的邮箱。

您确认发送到此邮箱。

敬请留意:如您使用126/163邮箱接收下载文献,可能出现延迟或文件丢失问题,温馨提示您使用其他地址,感谢您的关注!

免责声明

关闭